The decision to stop developing danuglipron adds to a string of setbacks in the pharmaceutical giant's bid to win a slice of ...

Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See ...

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

The North Texas hospital system joins over 400 other entities and a dozen state attorneys general suing over alleged ...

The news will intensify pressure on Pfizer Chief Executive Officer Albert Bourla, who has repeatedly pointed to the drugmaker ...

The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.

The U.S. is preparing to announce sweeping tariffs on pharmaceutical imports within the next two months, according to ...

Vandana Singh Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies Even as Donald Trump paused the reciprocal tariffs ...

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...

And while Trump has criticized Ireland for attracting big pharma companies, he’s also suggested he wants to reshore ...